Advertisement

Obesity Surgery

, Volume 19, Issue 1, pp 80–86 | Cite as

Elevated Concentrations of Liver Enzymes and Ferritin Identify a New Phenotype of Insulin Resistance: Effect of Weight Loss After Gastric Banding

  • Amalia Gastaldelli
  • Lucia Perego
  • Michele Paganelli
  • Giorgio Sesti
  • Marta Hribal
  • Alberto O. Chavez
  • Ralph A. DeFronzo
  • Antonio Pontiroli
  • Franco FolliEmail author
Research Article

Abstract

Background

Several studies have associated elevated liver enzymes (LFTs), obesity, and type 2 diabetes (T2DM), and a link has been established between insulin resistance (IR) and elevated ferritin concentrations. We examined the relationship between LFTs, ferritin, and IR in morbid obese subjects and the effect of weight loss after bariatric surgery.

Methods

We measured liver enzymes, ferritin, insulin resistance, and glucose tolerance (by OGTT) in 159 morbid obese subjects (BMI = 44.4 ± 0.4 kg/m2) at baseline, 6 months and 1 year after laparoscopic-adjustable-gastric banding (LAGB). Subjects were divided in two groups: increased LFTs (ALT > 30; AST/ALT < 1) vs. normal LFTs.

Results

A large proportion of morbid obese subjects had increased LFTs (44%) which were associated with increased IR and ferritin, suggesting potential liver disease. A majority of the morbidly obese with increased LFTs, IGT, and T2DM, were male and had almost double ferritin concentrations, strongly correlated with ALT (r = 0.43, p < 0.0001). Both ferritin and ALT correlated with waist circumference and IR. One year after, LAGB glucose tolerance improved, LFTs and IR were reduced; ferritin did not change significantly, but was still correlated with IR.

Conclusions

Ferritin may be an additional useful marker for more severe hepatic IR.

Keywords

Insulin Resistance Bariatric Surgery Waist Circumference Ferritin NASH 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We acknowledge the expert technical assistance of Roberta Petz, Emma Buzzigoli, Emma Di Gregorio, and Demetrio Ciociaro.

Sources of Funding

The study has been partially supported by startup funds from the University of Texas Health Science Center (Franco Folli), funds from the Italian National Research Council (Amalia Gastaldelli) and MURST (Antonio Pontiroli).

Disclosures

There are no conflicts of interest for this paper.

References

  1. 1.
    Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase and the 6-year risk of the metabolic syndrome in Caucasian men and women: the Hoorn Study. Diabet Med. 2007;24:430–5.CrossRefGoogle Scholar
  2. 2.
    Nannipieri M, Gonzales C, Baldi S, et al. Liver enzymes, the metabolic syndrome, and incident diabetes: the Mexico City diabetes study. Diabetes Care. 2005;28:1757–62.CrossRefGoogle Scholar
  3. 3.
    Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity. Clin Liver Dis. 2004;8:535–47, viii.CrossRefGoogle Scholar
  4. 4.
    Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–31.CrossRefGoogle Scholar
  5. 5.
    Haap M, Fritsche A, Mensing HJ, et al. Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. Ann Intern Med. 2003;139:869–71.CrossRefGoogle Scholar
  6. 6.
    Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917–23.CrossRefGoogle Scholar
  7. 7.
    Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab. 1999;84:1513–7.CrossRefGoogle Scholar
  8. 8.
    Knobler H, Schattner A, Zhornicki T, et al. Fatty liver—an additional and treatable feature of the insulin resistance syndrome. QJM. 1999;92:73–9.CrossRefGoogle Scholar
  9. 9.
    Hansen EN, Torquati A and Abumrad NN. Results of bariatric surgery. Annu Rev Nutr. 2006;26:481–511.CrossRefGoogle Scholar
  10. 10.
    Luyckx FH, Desaive C, Thiry A, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord. 1998;22:222–6.CrossRefGoogle Scholar
  11. 11.
    Tuomainen TP, Loft S, Nyyssonen K, et al. Body iron is a contributor to oxidative damage of DNA. Free Radic Res. 2007;41:324–8.CrossRefGoogle Scholar
  12. 12.
    Forouhi NG, Harding AH, Allison M, et al. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia. 2007;50:949–56.CrossRefGoogle Scholar
  13. 13.
    Bugianesi E, Manzini P, D'Antico S, et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology. 2004;39:179–87.CrossRefGoogle Scholar
  14. 14.
    Machado M, Cortez-Pinto H. NASH, insulin resistance and iron. Liver Int. 2006;26:1159–62.CrossRefGoogle Scholar
  15. 15.
    Pontiroli AE, Folli F, Paganelli M, et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity: a 4-year case-controlled study. Diabetes Care. 2005;28:2703–9.CrossRefGoogle Scholar
  16. 16.
    Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab. 2002;87:3555–61.CrossRefGoogle Scholar
  17. 17.
    Pontiroli AE, Pizzocri P, Paroni R, et al. Sympathetic overactivity, endothelial dysfunction, inflammation, and metabolic abnormalities cluster in grade III (World Health Organization) obesity: reversal through sustained weight loss obtained with laparoscopic adjustable gastric banding. Diabetes Care. 2006;29:2735–8.CrossRefGoogle Scholar
  18. 18.
    Mari A, Pacini G, Murphy E, et al. A model-based method for assessing insulin sensitivity from the oral glucose tolerance test. Diabetes Care. 2001;24:539–48.CrossRefGoogle Scholar
  19. 19.
    Matsuda M and DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22:1462–70.CrossRefGoogle Scholar
  20. 20.
    Muniyappa R, Lee S, Chen H, et al. Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage. Am J Physiol Endocrinol Metab. 2008;294:E15–26.CrossRefGoogle Scholar
  21. 21.
    Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402–10.CrossRefGoogle Scholar
  22. 22.
    Home PD and Pacini G. Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin-sensitizing agents. Diabetes Obes Metab. 2007.Google Scholar
  23. 23.
    DeFronzo RA, Ferrannini E and Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glucose production and impaired tissue glucose uptake. Metabolism. 1989;38:387–95.CrossRefGoogle Scholar
  24. 24.
    Sindelar DK, Chu CA, Venson P, et al. Basal hepatic glucose production is regulated by the portal vein insulin concentration. Diabetes. 1998;47:523–9.CrossRefGoogle Scholar
  25. 25.
    Wyatt SB, Winters KP and Dubbert PM. Overweight and obesity: prevalence, consequences, and causes of a growing public health problem. Am J Med Sci. 2006;331:166–74.CrossRefGoogle Scholar
  26. 26.
    Hanley AJ, Wagenknecht LE, Festa A, et al. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the Insulin Resistance Atherosclerosis Study. Diabetes Care. 2007;30:1819–27.CrossRefGoogle Scholar
  27. 27.
    Schindhelm RK, Diamant M, Dekker JM, et al. Alanine aminotransferase as a marker of non-alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22:437–43.CrossRefGoogle Scholar
  28. 28.
    Vari IS, Balkau B, Kettaneh A, et al. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR). Diabetes Care. 2007;30:1795–801.CrossRefGoogle Scholar
  29. 29.
    Zacharski LR, Ornstein DL, Woloshin S, et al. Association of age, sex, and race with body iron stores in adults: analysis of NHANES III data. Am Heart J. 2000;140:98–104.CrossRefGoogle Scholar
  30. 30.
    Moirand R, Mortaji A, Loreal O, et al. A new syndrome of liver iron overload with normal transferrin saturation. Lancet. 1997;349:95–7.CrossRefGoogle Scholar
  31. 31.
    Ferrannini E. Insulin resistance, iron, and the liver. Lancet. 2000;355:2181–2.CrossRefGoogle Scholar
  32. 32.
    Tuomainen TP, Diczfalusy U, Kaikkonen J, et al. Serum ferritin concentration is associated with plasma levels of cholesterol oxidation products in man. Free Radic Biol Med. 2003;35:922–8.CrossRefGoogle Scholar
  33. 33.
    Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull. 1993;49:642–52.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Amalia Gastaldelli
    • 1
  • Lucia Perego
    • 2
  • Michele Paganelli
    • 2
  • Giorgio Sesti
    • 4
  • Marta Hribal
    • 4
  • Alberto O. Chavez
    • 5
  • Ralph A. DeFronzo
    • 5
  • Antonio Pontiroli
    • 3
  • Franco Folli
    • 5
    Email author
  1. 1.Institute of Clinical PhysiologyNational Research Council PisaPisaItaly
  2. 2.Divisione di Medicina-Divisione de ChirurgiaOspedale San RaffaeleMilanItaly
  3. 3.Dipartimento di Medicina, Chirurgia e OdontoiatriaUniversity of MilanoMilanItaly
  4. 4.University of CatanzaroCatanzaroItaly
  5. 5.Diabetes Division, Department of MedicineUniversity of Texas Health Science CenterSan AntonioUSA

Personalised recommendations